CRUSE MICHAEL (Senior VP, Corporate Operation) purchased 7.25K shares of ONKURE THERAPEUTICS, INC. on the open market
Open‑market purchase worth $23.2K. The strongest form of insider conviction signal.
P · 5 purchases
Filed: 8/31/2022ACC: 0001209191-22-048167
Officer· Senior VP, Corporate Operation
Since Apr 2021
+7.25K
Net shares
Net buyer
$23.2K
Total acquired
5
Open market trades
5B · 0S
5
Total transactions
7.25K acquired
Non-Derivative Transactions5
Common Stock
Direct
Shares
+83.00
Price / share
$3.24
Trade value
$268.92
% of position
0.3%
8/29/2022
30.70K→30.78K
Common Stock
Indirect
Shares
+1.14K
Price / share
$3.24
Trade value
$3.69K
% of position
New position
8/29/2022
0.00→1.14K
Common Stock
Direct
Shares
+975.00
Price / share
$3.16
Trade value
$3.08K
% of position
3.2%
8/30/2022
30.78K→31.76K
Common Stock
Indirect
Shares
+1.84K
Price / share
$3.19
Trade value
$5.89K
% of position
161.8%
8/30/2022
1.14K→2.98K
Common Stock
Indirect
Shares
+3.21K
Price / share
$3.21
Trade value
$10.31K
% of position
107.6%
8/31/2022
2.98K→6.20K
Total
Net shares
+7.25K
Net value
$23.24K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/29/2022 | P · Purchase | +83.00 | $3.24 | $268.92 | 0.3% | 30.70K | 30.78K |
| Common Stock Indirect | 8/29/2022 | P · Purchase | +1.14K | $3.24 | $3.69K | New position | 0.00 | 1.14K |
| Common Stock Direct | 8/30/2022 | P · Purchase | +975.00 | $3.16 | $3.08K | 3.2% | 30.78K | 31.76K |
| Common Stock Indirect | 8/30/2022 | P · Purchase | +1.84K | $3.19 | $5.89K | 161.8% | 1.14K | 2.98K |
| Common Stock Indirect | 8/31/2022 | P · Purchase | +3.21K | $3.21 | $10.31K | 107.6% | 2.98K | 6.20K |
| Total | +7.25K | $23.24K | ||||||
Derivative Transactions0
No derivative transactions reported